Stock Market Reviews

Read and share opinions on CANF (Can-Fite BioPharma Ltd.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market.

Latest News

• Can-Fite Reports Complete Resolution of Esophageal Varices in Decompensated Cirrhosis Patient Treated with Namodenoson
  Sep 15, 2025
• Can-Fite Reports H1 2025 Financial Results and Clinical Update
  Aug 28, 2025
• Pancreatic Cancer Phase 2a Study with Can-Fite’s Namodenoson Achieved Over 50% Enrollment Milestone
  Jul 30, 2025
• Can-Fite Announces Up To $15.0 Million Public Offering
  Jul 28, 2025
• Breakthrough Study from UCLA Demonstrate Can-Fite’s Piclidenoson as a Treatment for Vascular Dementia
  Jul 28, 2025
• Can-Fite to Present Phase IIa Pancreatic Cancer Study Progress During Partnering Meetings at the 2025 BIO International Convention in Boston
  Jun 16, 2025
• Can-Fite Has Raised $175 Million in Total to Date for the Development of Namodenoson and Piclidenoson, Advancing into Pivotal Phase 3 Trials in Liver Cancer and Psoriasis
  May 5, 2025
• Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite’s Namodenoson, Leading U.S. Medical Centers Seek Authorization for their Patients
  Apr 17, 2025
• Can-Fite Announces $3.0 Million Registered Direct Offering of American Depositary Shares
  Apr 14, 2025
• Can-Fite to Generate $685M in Projected Future Revenues from its Partnerships
  Apr 14, 2025
• Can-Fite Reports 2024 Financial Results and Clinical Update
  Apr 14, 2025
• bioAffinity Technologies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
  Mar 28, 2025
• Can-Fite Initiates Pivotal Phase 3 Psoriasis Study of its Oral Drug Piclidenoson with FDA & EMA-Approved Protocol
  Mar 24, 2025
• Can-Fite Partner Vetbiolix Accelerate Piclidenoson Development with Advanced Clinical Trial for Canine Osteoarthritis in a $3.8 Billion Market
  Mar 20, 2025
• Can-Fite to Initiate Phase II Study in the Rare Genetic Disease Lowe Syndrome with Piclidenoson
  Mar 19, 2025
• Can-Fite: FDA Approved Compassionate Use Treatment with Namodenoson in a Pancreatic Cancer Patient
  Mar 18, 2025
• Can-Fite Innovative Publication: Namodenoson in Liver Cancer Treatment Alongside with Cardiac, Liver, and Neurological Benefits
  Mar 3, 2025
• Disappearance of Decompensated Liver Cirrhosis Episodes After Treatment with Can-Fite's Namodenoson
  Feb 18, 2025
• Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on February 25
  Feb 10, 2025
• Can-Fite BioPharma to Present the Namodenoson Anti-Obesity Effect at BIO CEO & Investor Conference 2025
  Feb 5, 2025